BioSpace News Archive

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced updated results from a Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients newly diagnosed with FLT3 mutation-positive (FLT3mut+) Acute Myeloid Leukemia (AML).

Technavio analysts forecast the global ocular inflammation treatment market to grow at a CAGR of more than 6% during the forecast period, according to their latest market research report

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®) from the ongoing HORIZON trial at the 60th ASH meeting in San Diego, California, USA.

Synchron Inc., a company developing minimally invasive neural interface technology, today announced data demonstrating the feasibility of minimally-invasive techniques to enable focal brain stimulation has been published in the journal Nature Biomedical Engineering

“I’m a nurse and I thought there could be a better tourniquet option when inserting PICC lines,” said an inventor, from Santa Ana, Calif., “so I invented the patent pending HANDS-FREE PICC LINE TOURNIQUET.”

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.

AbbVie, a research-based global biopharmaceutical company, today announced a historic $50 million donation to St. Jude Children’s Research Hospital®

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., announced results of a large, Phase 3, multicenter, open-label safety study of its lead investigational antiepileptic drug, cenobamate (YKP3089), at the American Epilepsy Society (AES) Annual Meeting in New Orleans (November 30 – December 4).

Health Union was recognized today as the No. 1 company in the Medium Agency category in Medical Marketing & Media’s (MM&M) inaugural Best Places to Work Class of 2018.

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on advanced non-small cell lung cancer (NSCLC) on Tuesday, Dec. 11 from 5 to 9 p.m. at the Kansas City Marriott Downtown in Kansas City, Missouri.